ACER 外汇新闻
Acer Therapeutics Resubmits NDA For ACER-001 For Treatment Of Urea Cycle Disorders
Pharmaceutical company Acer Therapeutics Inc. (ACER) announced Monday the resubmission of Acer's New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs).
RTTNews
|
890天前
Acer Therapeutics, Relief Therapeutics Receive CRL From FDA For ACER-001 For UCDs
Pharmaceutical company Acer Therapeutics Inc. (ACER) and its collaboration partner, Relief Therapeutics Holding SA (RLFTF, RLFTY), announced Tuesday that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs).
RTTNews
|
917天前
